With the passage of the sweeping health care reform late Sunday night, many investors are scrambling to determine which sectors are likely to benefit from the new legislation. Although the timing and impact of changes remains to be seen, generic pharmaceutical firms will likely emerge as one of the big winners. Many big name drugs [...] Related Stories: Health Care ETFs In Focus After Historic Vote Israel ETF (EIS) Surges Ahead Pharma ETFs in Focus: Obama’s Reform and Swine Flu’s Sting